Exelixis (NASDAQ: EXEL ) had a great day in the market today, up 23% on the news that its drug cobimetinib in combination with Roche's (NASDAQOTH: RHHBY ) drug Zelboraf succeeded in a phase 3 trial's primary endpoint of extending progression-free survival.
Of course, cobimetinib isn't all investors should think about regarding Exelixis: Cometriq will also be important. In the video below, health care analysts Michael Douglass and David Williamson give their take on Exelixis.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Report this Comment On July 14, 2014, at 7:30 PM, DNAstock wrote:
Michael, dude, if you're going to be talking about this stuff, at least learn how to pronounce the words.
B-raf (pronunciation: bee-raf, not "braf")
Gemcitabine (pronunciation: jem-SITE-a-been)
Cobimetinib (pronunciation: ko-bee-met-tin-ib)
Report this Comment On July 15, 2014, at 3:35 PM, TepperMay wrote:
William Blair Reiterates Outperform On Exelixis Following Positive Phase 3 Results http://bit.ly/1nDOFT3
Add your comment.